Patents by Inventor Hans-Ake Fabricius

Hans-Ake Fabricius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10098906
    Abstract: The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: October 16, 2018
    Assignee: CELL RECEPTOR AG
    Inventor: Hans-Ake Fabricius
  • Publication number: 20160367589
    Abstract: The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.
    Type: Application
    Filed: October 22, 2014
    Publication date: December 22, 2016
    Applicant: Cell Receptor GmbH
    Inventor: Hans-Ake FABRICIUS
  • Patent number: 5093479
    Abstract: An interleukin-1 preparation is obtained as a supernatant by cell culturing human peripheral mononuclear blood cells.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: March 3, 1992
    Assignee: Shanksville Corp. N.V.
    Inventors: Hans-Ake Fabricius, Eckart Kottgen
  • Patent number: 4808533
    Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free and mitogen-free interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth.
    Type: Grant
    Filed: May 3, 1985
    Date of Patent: February 28, 1989
    Assignee: Shanksville Corporation NV
    Inventors: Hans-Ake Fabricius, Eckart U. Kottgen
  • Patent number: 4681844
    Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free- and mitogen-free Interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth.
    Type: Grant
    Filed: May 3, 1985
    Date of Patent: July 21, 1987
    Assignee: Shanksville Corporation N.V.
    Inventors: Hans-Ake Fabricius, Eckart U. Kottgen
  • Patent number: 4661447
    Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free- and mitogen-free Interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth.
    Type: Grant
    Filed: July 15, 1983
    Date of Patent: April 28, 1987
    Assignee: Shanksville Corporation N.V.
    Inventors: Hans-Ake Fabricius, Eckart U. Kottgen
  • Patent number: 4464355
    Abstract: A serum-free and mitogen-free T-cell growth factor which is effective in stimulating natural killer cell function in tumor patients is provided. A method of producing the growth factor from human, bovine or porcine spleen or blood is described.
    Type: Grant
    Filed: September 3, 1982
    Date of Patent: August 7, 1984
    Assignee: Hooper Trading Co.
    Inventors: Hans-Ake Fabricius, Roland Stahn
  • Patent number: 4448879
    Abstract: An improved in vitro cell culture process for producing in high yield and purity a serum-free and mitogen-free interleukin-2-containing conditioned supernatant. The incubation steps during stimulation and conditioning of the interleukin-2 producing cells is carried out with a rapidly rotating roller bottle culture system. Yields of interleukin-2 are on the order of 10-fold and higher than obtained by similar cultivations carried out in flat dishes or tubes or in a roller bottle culture system rotated at conventional speeds. Improvement in yields in both the static and roller culture systems are also achieved by incubating the IL-2 producing cells under high oxygen concentrations, for example atmospheres of at least 70% O.sub.2 and at least 5% CO.sub.2. In addition to using peripheral mononuclear blood cells (PBL) as the source of leukocytes containing the IL-2 producer cells, it is also possible to use buffy coat cells which are readily available as a waste by-product from blood banks.
    Type: Grant
    Filed: September 15, 1982
    Date of Patent: May 15, 1984
    Assignee: Hooper Trading Company
    Inventors: Hans-Ake Fabricius, Roland Stahn
  • Patent number: 4406830
    Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligant Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free- and mitogen-free Interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth.
    Type: Grant
    Filed: April 17, 1981
    Date of Patent: September 27, 1983
    Assignee: Shanksville Corporation, N.V.
    Inventors: Hans-Ake Fabricius, Eckart U. Kottgen
  • Patent number: 4388309
    Abstract: Suppression of the immunological rejection mechanism of a host which has received an organ transplant in achieved by the daily administration to the host of a ganglioside agent which effectively blocks the soluble immunological cell mediator interleukin 2 and /or a blastogenic factor. By binding to the mediator for T cell blast formation the mediator is prevented from binding to the asialo GM1 receptor on the surface of the T effector cell. Blastogenesis does not occur and the cell mediated rejection of the graft is prevented.
    Type: Grant
    Filed: June 10, 1981
    Date of Patent: June 14, 1983
    Assignee: Shanksville Corporation, N.V.
    Inventors: Hans-Ake Fabricius, Eckart U. Kottgen